Navigation Links
OncoSec Medical Featured in Medical Device Daily
Date:5/9/2011

SAN DIEGO, May 9, 2011 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), a therapeutic oncology company developing innovative medical approaches to treat solid tumor cancers with unmet medical needs, announced today the cancer therapy company's tumor-destroying, tissue-sparing drug/device technology was profiled in Medical Device Daily, the news source for the high-tech medical technology industry that is relied on by thousands of industry insiders every business morning.

(Logo:  http://photos.prnewswire.com/prnh/20110314/MM64943LOGO)

The article noted that OncoSec is leveraging the successful treatment of cancers in early and late stage clinical trials of more than 400 patients to advance its proprietary drug technology delivery system, which enables highly targeted delivery of chemotherapy agents and DNA-based immunotherapies into solid tumors.

The article quoted OncoSec's CEO, Punit Dhillon, who said:  "...[OncoSec] is not your typical startup because we're leveraging a lot of historical and clinical data, along with clinical experience."

Dhillon foresees a large market opportunity for the OncoSec drug/device treatment system: "Our conservative estimate is at least four million people in the U.S.  Where the larger market lies is in emerging markets. That could exponentially increase [the market]," he said.

The full article can be found at: http://www.medicaldevicedaily.com/servlet/com.accumedia.web.Dispatcher?next=bioWorldHeadlines_article&forceid=75423

About OncoSec Medical Inc.

OncoSec Medical's (OTCBB: ONCS) novel ElectroOncology therapies combine its proprietary electroporation delivery technology with a chemotherapeutic or novel DNA-based immunotherapeutics. Targeted local delivery of these agents achieves selective destruction of cancerous tumors while sparing healthy normal tissue, resulting in improved functional, cosmetic and quality of life outcomes.  These therapies have achieved validating safety and efficacy data in early and late stage clinical studies of over 400 cancer patients. More information is available at www.oncosec.com.

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec's filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE OncoSec Medical Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. OncoSec Medical Appoints Punit Dhillon as President and CEO
2. Reportlinker Adds Medical Enzymes: Technologies and Global Markets
3. Saladax Biomedical, Inc. Announces European Commercialization Team
4. Dune Medicals MarginProbeâ„¢ Demonstrates Increased Positive Margin Identification Leading to Reduction in Patients Indicated for Re-excision in Landmark Lumpectomy Surgery Trial
5. Optimer Pharmaceuticals and Clinical Investigators to Present Data at Upcoming Medical Meetings
6. USC and Coulter Foundation Partner to Invest $5M in Breakthrough Innovation in Biomedical Engineering
7. AAPC Lowers Prices on Medical Coding Books, Again
8. Keynote Announced for Virtual Event: Developments in Materials for Medical Applications
9. KellBenx Secures Worldwide Agreement With Cedars-Sinai Medical Center for Biomarker Technology to Predict Premature Births
10. Biotech Medical, Inc. Introduces a Full Line of Enzyme Cleaners
11. Beijing Chaoyang District Court Grants Investigation Letters Against Inverness Medical Beijing, A Subsidiary of Alere Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... , March 24, 2017 Sinovac Biotech Ltd. ("Sinovac" or ... China , today announced that its board of ... date of the plan from March 27, 2017 to March 27, ... About Sinovac Biotech Ltd. ... Sinovac Biotech Ltd. is a ...
(Date:3/24/2017)... LEXINGTON, Mass. , March 24, 2017 ... pipeline of immune checkpoint antibodies and cancer vaccines, today ... The 7 th  Annual William Blair and Maidstone ... Event Space Alexandria Center in New York, ... March 29 at 9:40 am: ...
(Date:3/23/2017)... Research and Markets has announced the addition of ... offering. ... The Global Market for Bioproducts Should Reach $714.6 Billion ... of 8.9%, This research report quantifies the ... product segments: bio-derived chemicals, biofuels, pharmaceuticals (biodrugs and herbal/botanicals), biocomposite ...
(Date:3/23/2017)... , March 23, 2017  GlobeImmune, Inc. today ... for the sale of 12,835,490 shares of its common ...  ecosystem of companies. In connection with the sale of its ... in cash and issue to GlobeImmune 200,000 shares, an ... "We are pleased to enter into ...
Breaking Biology Technology:
(Date:2/13/2017)... , Feb. 13, 2017  RSA Conference -- RSA, ... that is designed to enhance fraud detection and ... in the RSA Fraud & Risk Intelligence Suite. ... to leverage additional insights from internal and external ... better protect their customers from targeted cybercrime attacks. ...
(Date:2/9/2017)... LONDON , Feb. 9, 2017 The ... in-depth analysis of the biomass boiler market globally in ... sales of biomass boilers. The market for biomass boilers ... product type, end-user, application, and country/region. The market based ... agriculture & forest residues, biogas & energy crops, urban ...
(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... The global synthetic-biology ... $11.4 billion by 2021, growing at a compound annual growth ... An overview of the global markets for synthetic biology. - ... for 2016, and projections of compound annual growth rates (CAGRs) ...
Breaking Biology News(10 mins):